ArticleRenal failure2025
Gut microbiome and peritoneal inflammation: a new perspective on peritoneal dialysis-associated peritonitis.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protecting peritoneal dialysis patients: evaluation and prevention strategies for noninfectious risk factors.Renal failure · 2026Review
- Ameliorative Effects of Schisandrol A on Lipopolysaccharide-Induced Intestinal Injury in Mice.Nutrients · 2026Article
- Prediction of Imminent Peritoneal Dialysis-Associated Peritonitis Using Time-Updated Electronic Health Records and Machine Learning: A Temporal Validation Study.Journal of inflammation research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGut microbiome disorders and intestinal barrier damage were found in peritonitis. However, the relationship between the gut microbiome and peritoneal dialysis-associated peritonitis (PDAP) remains unknown. This study aimed to investigate the role of the gut microbiome in PDAP and explore its correlation with intra-abdominal inflammation.
methodsWe used a two-fold strategy to investigate the causal relationship between the gut microbiome and PDAP. First, a Mendelian randomization (MR) study was conducted using summarized statistics from genome-wide association studies (GWAS) of the gut microbiome and peritonitis. Additionally, a case-control study with 24 patients from the peritoneal dialysis (PD) and PDAP groups were conducted to validate the role of candidate bacteria in peritonitis, using 16S rRNA sequencing to capture their gut microbiomes.
resultsWe screened four protective and one risky bacteria for peritonitis using MR analysis. The results of MR analysis were validated in the case-control study. We observed a shift in the co-occurrence pattern from the PD group to the PDAP group, suggesting potential destabilization of the gut bacterial network in the PDAP group. Furthermore, analysis of 17 protective and three risky bacteria revealed differential bacteria through LefSe and random forest analyses. Among these, we observed a significant negative correlation between
conclusionGut microbiome dysbiosis in peritoneal dialysis patients is a significant contributing factor to PDAP, with alterations in microbial abundance showing a strong correlation with the severity of intraperitoneal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.